Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: JAMA Neurol. 2016 May 1;73(5):535–541. doi: 10.1001/jamaneurol.2016.0031

Table 2.

Adjusted HRs for 180-Day Mortality in AP-Exposed vs Non–AP-Exposed Patients

Group HR (95% CI) P Valuea
Intention-to-treat analysis
 No AP exposure 1 [Reference] NA
 AP exposure 2.35 (2.08–2.66) <.001
 AP exposure by type
  No AP exposure 1 [Reference] NA
  Atypical AP exposure 2.26 (1.98–2.57) <.001
  Typical AP exposure 3.65 (2.47–5.39) <.001
Exposure-only analysis
 No AP exposure 1 [Reference] NA
 AP use 2.15 (1.82–2.55) <.001
 AP exposure by type
  No AP exposure 1 [Reference] NA
  Atypical AP exposure 2.09 (1.75–2.49) <.001
  Typical AP exposure 3.11 (1.72–5.60) <.001

Abbreviations: AP, antipsychotic; HR, hazard ratio; NA, not applicable.

a

Obtained from testing for the significance of the covariate estimates obtained from the corresponding Cox proportional hazards regression model.